With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

Ever since its launch in 2020, backed by Versant and venBio, RayzeBio has talked at length about building a platform company to fulfill the potential that radiopharmaceuticals hold — with seven active programs to boast. But it’s stayed mum about what those programs actually are, instead sticking to updates about new funding, hires or partnerships.